






既存の抗癌剤感受性試験であるhuman tumor clonogenic assay (HTCA) ,腎被膜下移植法




































Abbreviations: ADR, adriamycin; BLM, bleomycin; CDDP, cisplatin; DF-10,
Dulbecco's modified Eagle's medium contains lO% fetal bovine serum; DMEM,
Dulbecco's modified Eagle's medium ; EDTA, ethilendiaminetetraacetic acid ; FBS, fetal





















modified Eagle's medium, DMEM) (日本製薬.東







Laboratories, U. S. A.)を用いて細胞浮遊液を作成
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Table 1. Plating efficiency of NCC-nu, HeLa and PLC cells
plating efficiency (%)a in the inoculation








a) Dishes were inoculated with each number of cells and
incubated for 7 days under 5% CO2 gass. Then number




I., labeling index ;
R., survival rate :
Number of colonies formed
Number of cells inoculated×100
IC恥90% growth inhibitory concentration ; LD恥50% lethal dose ; L.
M. Ⅰリmitotic index; MMC, mitomycin C; MTX, methotrexate; S.
















め0.1% RNase (Sigma Chem. Co., U. S. A.)を用
い, 37oC, 30分間処理した.その後ハンクス液にて1
回洗浄の後, 50JJg/mlプロビディウムイオダイド6)


































bed with 0.25% trypsin and 0.02% EDTA
by90% DMEM with lO% FBCS
count by trypan blue
ilated with 200 cells/dish
ired for 24 hr at 37℃
ncer drug contact for 2 hr at 37℃
d by Hanks solution, × 3
red for 7 days at 37℃
iy count by ¥% crystal violet




IOmg, CDDP IOOmg　とすると薬剤濃度は, ADR





























Incubated with anticancer drug for 2 hr at 37oC
J
Rinsed by Hanks'solution, × 3
J
Cultured for 6, 12, and 24 hr at 37oC
J
Detached with 0.25% trypsin and 0.02% EOTA
J
Fixed with 70% ethanol
J
Treated with RNase for 30 min at 37℃
J
Stained by 50 jj,g/ml propidium iodide
J
Analysis of cell cycle by FCM (CS-20)




























































Fig. 4. Dose･survival curve of cells treated with
drugs.The cells were exposed to different
concentratiorl of the drugs in medium for 2hr.
After exposure, the drugs were removed and
cells were washed three times with Hanks'sol-
ution. Then the cells were cultured for　7
days. Survival rate of the cells was determi-
ned by colony forming assay. o, NCC-nu
cells;汁, HeLa cells; ▲, PLC cells, (a) The
cells were treated with adriamycin (ADR). (ち)
The cells were treated with mitomycin (MM-





は通常ADR 20mg, MMC IOmg, CDDP IOOmgを使
用しており,それぞれの投与量での理論的最高血中
濃度は,循環血液量を5L　とした場合ADR4〟g/
ml, MMC 2/*g/ml, CDDP 20//g/mlと考えられる･
固形腰痛では理論的最高血中濃度の1 /10が移行する
とされており,理論的組織内濃度はそれぞれADR





0.8, MMC 0.4の順であった. HeLa細胞では, ADR























Table2. Jn vitro chemosensitivity of
NCC-nu, HeLa and PLC cells
ICgo value (〃g/ml) of
Kind of



























































a) clinical dose - regular clinical dose/
body blood volume (51). Regular clini-
cal dose: ADR, 20mg; MMC, lOmg;


























































Fig. 5. Survival rate and time course
(a) NCC-nu cells treated with ADR.
(b) HeLa cells treated with ADR.
(c) PLC cells treated with ADR.
(d) NCC-nu cells treated with MMC.
(e) HeLa cells treated with MMC.
(f) PLC cells treated with MMC.
(g) NCC-nu cells treated with CDDP.
(h) HeLa cells treated with CDDP.






































































Fig. 6. Dose-response curve of cells on flowcyt-
ometry (FCM) treated with drugs. The cells
were exposed to different concentration of the
drugs in medium for 24 hr. After exposure,
the cells were removed and cells were washed
three times with Hanks' solution. Then the
cells were cultured for 24 hr. The percentage
of S　+GM on cell cycle was analysed by
Fried's DNA analysis.
(a) The cells were treated with ADR.
(b) The cells were treated with MMC.
(c) The cells were treated with CDDP.
o, NCC-nu cells;卑, HeLa cells; A, PLC
cells.






















































Fig. 7. Relationship between survival rate and
ratio of S+CM. Survival rate of the cells
was determined by colony forming assay.
Ratio of S+G:M of the cells was determined
by Fried's UNA analysis. The results are
shown as mean of data.
(a) The cells were treated with ADR.
0, NCC-nu cells, Y- -0.003X+ 1.409,(r- -
0.963, p<0.001);虫, HeLa cells, Y- -0.008+
1.374 (r--0.862, p<0.05); A, PLCcells, Y--
0.006X+1.475 (r- -0.995, p<0.001) ;
(b) The cells were treated with MMC.
0, NCC-nu cells, Y- -0.002X+1.318 (r= -
0.971, p<0.001) ; B, HeLa cells, Y=-0.004X+
1.318 (r--0.984, p<0.001); ▲　PLC cells, Y=
-0.003X+1.248 (r- -0.997, p<0.001) ;
(c) The cells were treated with CDDP.
0, NCC-nu cells, Y- -0.003X+1.244 (r- -
0.990, p<0.001) ; B, HeLa cells, Y=-0.005X+
1.298 (r--0.980, p<0.001) ▲, PLC cells, Y-
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Experimental Study on Chemosensitivity Test for Anticancer Drugs Using
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Abstract
The determination of a chemosensitivity for an individual cancer patient is possibly
required within a short time, because suitable anticancer drugs should be given to the
patient immediately after surgery.　However, well-known chemosensitivity tests, such as
tumor xenograft to athymic mice, human tumor clonogenic assay (HTCA) and subrenal
capsule assay (SRC), usually take more than 7 days. For this reason, the auther attempted
to establish a rapid chemosensitivity test using flowcytometry (FCM). Since the cell cycle
or tumor cells is changed after treatment with anticancer drugs, the sensitivity can be
determinedby a DNA histogram using Frieds DNA analysis. Three human tumor cell
lines, NCC-nu, HeLa, and PLC, were used in this assay, and mitomycin C (MMC),
adriamycin (ADR), and cisplatin (CDDP) were tested. The drug concentration used in
this assay was determined by the theoretical concentration of human tissues.　The
accumulation of DNA in S- and G2M-phase was recognized 12 hours after drug exposure
and distinctively changed 24 hours after. The ratio of the accumulation of DNA in S- and
G2M-phase treated with drugs to that of control (ratio of S+G2M) was calculated. The
ratio of S+G2M increased in proportion to the concentration of drugs. To compare the
ratio of S+GヱM with cytotoxicity, the cytotoxic effect of the drugs in vitro was also tested
by colony forming assay according to the method of Puck and Marcus. There is a good
correlation between the ratio of S+G.M and cytotoxicity.　When the ratio of S+G2M
exceeded 1.3 at the concentration of clinical dose, the cells showed high sensitivity to the
824 管
drugs. However, low sensitivity cells did not exceed 1.3. These results showed that the
ratio of S+G.M exceeding 1.3 at the concentration of clinical dose might be available as a
criterion of chemosensitivity. This study indicates that DNA analysis using FCM offers
the possibility of a new chemosensitivity test.
